Geographic atrophy Trials in Fullerton, United States
Conditions / Geographic atrophy / Fullerton, United States
Clinical trials for Geographic atrophy investigate a range of treatment strategies and patient populations.
14 total trials for this combination
Showing top 10 of 14 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05811351 | A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) | COMPLETED | PHASE2 |
| NCT06510816 | A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Geographic Atrophy (GA) | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT04465955 | A Study of NGM621 in Participants With Geographic Atrophy | COMPLETED | PHASE2 |
| NCT04435366 | A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor) | COMPLETED | PHASE3 |
| NCT02745119 | Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT) | TERMINATED | PHASE3 |
| NCT02247531 | A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | TERMINATED | PHASE3 |
| NCT05019521 | A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | TERMINATED | PHASE2 |
| NCT05536297 | Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy | COMPLETED | — |
| NCT06635148 | A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) | RECRUITING | PHASE2 |
| NCT03525613 | A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration | COMPLETED | PHASE3 |